Complete and Durable Response to Tamoxifen and Ovarian Ablation in the Treatment of Metastatic Breast Cancer

Most breast cancers are hormone receptor-positive, and tamoxifen is the mainstay of endocrine therapy for such patients. However, with the introduction of aromatase inhibitors and then fulvestrant, tamoxifen became a less preferred drug, even in a premenopausal setting. Many new approaches to tackle...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel-Razeq, Hikmat, Abunasser, Mahmoud, Farfoura, Heba, Abdel-Razeq, Rshid, Khzouz, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065093/
https://www.ncbi.nlm.nih.gov/pubmed/33907637
http://dx.doi.org/10.7759/cureus.14088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065093/
https://www.ncbi.nlm.nih.gov/pubmed/33907637
http://dx.doi.org/10.7759/cureus.14088

Ejemplares similares